Amelioration of rat cardiac cold ischemia/reperfusion injury with inhaled hydrogen or carbon monoxide, or both.
Atsunori Nakao, David J Kaczorowski, Yinna Wang, Jon S Cardinal, Bettina M Buchholz, Ryujiro Sugimoto, Kimimasa Tobita, Sungsoo Lee, Yoshiya Toyoda, Timothy R Billiar, Kenneth R McCurry · The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2010
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
This narrative review examined this study was designed to evaluate the effects of inhaled hydrogen or CO, or both, on cold ischemia/reperfusion (I/R) injury of the myocardium. Hydrogen treatment alone significantly reduced malondialdehyde levels and serum high-mobility group box 1 protein levels as compared with air-treated controls. The reviewed evidence adds support for molecular hydrogen's therapeutic potential across the conditions, mechanisms, or outcomes examined.
What the Findings Mean
H2HUBB reviewed this publication as a synthesis of molecular-hydrogen research and summarizes the outcomes emphasized by the authors. Dual treatment with hydrogen and CO significantly attenuated I/R graft injury, reducing the infarcted area and decreasing in serum troponin I and creatine phosphokinase (CPK).
What the Researchers Studied
The authors reviewed this study was designed to evaluate the effects of inhaled hydrogen or CO, or both, on cold ischemia/reperfusion (I/R) injury of the myocardium.
What Effects Did Molecular Hydrogen Have?
Source-reported hydrogen concentration: 3% source-reported H₂ gas concentration; Source-reported hydrogen exposure: 3% source-reported H₂ gas concentration; reported treatment duration: 1 hour. Dual treatment with hydrogen and CO significantly attenuated I/R graft injury, reducing the infarcted area and decreasing in serum troponin I and creatine phosphokinase (CPK). The authors concluded that combined therapy with hydrogen and CO demonstrated enhanced therapeutic efficacy via both anti-oxidant and anti-inflammatory mechanisms, and may be a clinically feasible approach for preventing cold I/R injury of the myocardium.
Why These Findings Matter
The reviewed evidence adds support for molecular hydrogen's therapeutic potential across the conditions, mechanisms, or outcomes examined.
How Strong Is This Evidence?
This is review or synthesis evidence (narrative review).
Technical Study Details
H2HUBB classifies this publication as narrative review with review or synthesis evidence. The study used a narrative review. The source-reported hydrogen concentration was 3% source-reported H₂ gas concentration. The reported treatment duration was 1 hour.
Limitations and Safety
No separate limitations or safety findings were identified in the current-study source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.